Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

tRNADiagnostics

Financiado

Cerrado

Simple and cost effective cancer diagnosis in liquid biopsy through native tRNA...

Simple and cost effective cancer diagnosis in liquid biopsy through native tRNA sequencing Transfer RNAs (tRNAs) are abundant, heavily-modified small non-coding RNAs that play a pivotal role in decoding genetic information, determining which transcripts are highly and poorly translated at a given moment. Dysregulation o... ver más

30/06/2026

FUNDACIO PRIVADA C...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-04

ERC-2024-POC: ERC PROOF OF CONCEPT GRANTS Objective:ObjectivesThe ERC Proof of Concept Grants aim at facilitating exploration of the commercia...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACIO PRIVADA CENTRE DE R...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 20 meses Fecha Inicio: 2024-10-04
Fecha Fin: 2026-06-30

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Transfer RNAs (tRNAs) are abundant, heavily-modified small non-coding RNAs that play a pivotal role in decoding genetic information, determining which transcripts are highly and poorly translated at a given moment. Dysregulation of tRNA abundances and tRNA modifications is a well-known feature in cancer cells, leading to enhanced translation of specific oncogenic proteins. Despite the well-established association between tRNA dysregulation and cancer progression and malignancy, tRNA abundances and their modifications are still not being used as diagnostic or prognostic markers for cancer detection or progression, mainly due to the lack of a simple, unbiased and cost-effective method to quantify tRNA abundances and their modifications. Our laboratory has recently established Nano-tRNAseq, a pioneering method that can accurately quantify both tRNA abundances and tRNA modifications using native tRNA nanopore sequencing, for a fraction of the cost of next-generation sequencing-based approaches. By employing a proprietary Nano-tRNAseq nanopore library preparation protocol coupled with deep learning algorithms that will rapidly classify the nanopore current signals, here we aim to establish a method that exploits tRNAs as novel biomarkers through the use of third generation sequencing technologies. We have initial evidence of how our approach can separate cancer from non-cancer samples and possibly be used to identify the tissue of origin. In this project, we will fully validate our technological platform for the differential analysis of low-input RNA amounts in liquid biopsy samples. We will initially apply our method in the cancer arena, expandable to many other indications, following the advice of key stakeholders contacted so far, with the goal of laying the basis for the transfer of our technology to the marketplace, including through the creation of a new start-up company.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores